Diagnostics, Genetics, Imaging

PARP Inhibitors and Prostate Cancer- Keeping Cancer Cells From Repairing Themselves

Drugs targeting poly (ADP-ribose) polymerase (PARP) are helping patients battle back more effectively against cancer. An enzyme, PARP helps repair damaged DNA in cells, and while that’s a good thing in healthy people, it can be bad news for cancer patients. To prevent PARP from repairing DNA breaks in cancer cells, AstraZeneca developed Lynparza, a PARP inhibitor (PARPi) more »

Obtaining Genetic Information Which Could Be Applicable to One’s Cancer

DNA sequencing of a person’s tumor can be very important in determining treatment plans among other potential applications. The National Cancer Institute (NCI) today published an excellent review of methods used to obtain a person’s genetic information and how this information could be applied. It is written in a way that can be clearly understood more »

Prostate Cancer Symptoms May Not Always Be Obvious

An article from Fox Chase Cancer Center in Philadelphia published Sept. 21st in the U.S. National Library of Medicine MedlinePlus described a list prostate cancer symptoms. Prostate cancer symptoms may be confused with signs of other common but noncancerous disorders, such as benign prostatic hyperplasia. Symptoms of prostate cancer may include: trouble starting to urinate; weak or more »

Everything You Need to Know About the PSA Test from the National Cancer Institute

The National Cancer Institute (NCI, the largest of the institutes of the National Institutes of Health, NIH) recently published an excellent fact sheet describing many aspects related to prostate-specific antigen (PSA) testing. Specific subjects addressed include: a) what is the PSA test? b) Is the PSA test recommended for prostate cancer screening? c) What is a more »

Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer

Testing for two biomarkers in urine may help some men avoid having to undergo an unnecessary biopsy to detect a suspected prostate cancer, findings from a new study show. In the NCI-supported study, researchers from Emory University in Atlanta and M.D. Anderson in Houston tested urine samples from men referred for a prostate biopsy for elevated more »

A Testimonial to Treating a Gene Involved in Metastatic Prostate Cancer

This linked article is an excellent personalized example of treating a man with metastatic prostate cancer and a mutated genetic defect in his BRCA2 gene. He was treated with the PARP inhibitor olaparib which is approved for ovarian cancer. The story itself needs little comment so I urge you to read the following link from more »

A Concise Prostate Cancer Resource Starting With Early Detection and Screening.

The Prostate Cancer Foundation published a fairly comprehensive yet concise e mail resource describing various facets of prostate cancer beginning with early screening and detection. The reader is urged to spend some time perusing this article. There is so much information here that I am simply linking the article at this point. The initial portion more »

Qiagen to Market AR-V7 Genetic Test That Shows If Prostate Cancer Responds to Enzalutamide (Xtandi) or Abiraterone (Zytiga).

Enzalutamide (Xtandi®) and abiraterone acetate (Zytiga®) are two approved hormone therapies commonly prescribed for men with hormone-resistant advanced prostate cancer. They block the androgen receptor signaling that is essential to the cancer’s growth. Although they represent breakthroughs in metastatic treatment, 20 to 40 percent of patients fail to respond to them.  These men with advanced more »

Updated PSA Screening Guidelines Now Stress Patient Choice

When three different prostate cancer websites post the same subject article, it is significant. According to the April 11th MedLinePlus from the U.S. National Library of Medicine, in a significant shift, a key health advisory panel plans to soften its recommendation against prostate-specific antigen (PSA) screening for detecting prostate cancer. In 2012, the U.S. Preventive Services more »

Men in Their 20’s and 30’s With a Specific Early Balding Pattern May Be at Higher Risk of Aggressive Prostate Cancer

When I come across a newsworthy article of interest, I usually summarize it on this post and link the reader to the entire article for more information. This is an exception as the original article from the Prostate Cancer Foundation (March 30th, 2017) contains specific visual and verbal information; hence I refer you to the more »

Predicting Prostate Cancer Metastasis and Mortality Using Decipher Genomic Score

The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality (PCSM) using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen (hormonal) deprivation, according to a mixed-cohort study presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida. Decipher more »

Identifying Suitable Candidates for Active Surveillance in Prostate Cancer

This review is designed for physicians and patients who have access to multiparametric MRI technology available in several major health research institutions. A recent article by Drs. Peter Choyke and Stacy Loeb  (from the National Cancer Institute, NIH) in the journal Oncology and e mailed through the CancerNetwork provided a important summary of active surveillance, more »

An Excellent Review of Current Imaging and Positron Emission Tomography (PET) Scanning and Their Use in Managing Recurrent and Advanced Disease

This website initially posted a review of positron emission tomography (PET) scanning on March 9th, 2015. More recently, the Prostate Cancer Research Institute (PCRI) November Insights contained an updated and very informative review of the latest PET imaging techniques for managing recurrent and advanced prostate cancer. Their major utilities, advantages and their limitations are discussed more »

Men with Advanced Prostate Cancer Should Consider Genetic Testing

In the light of recent discoveries (recently posted on this website) that some advanced prostate cancer patients harbor specific genetic mutations, a recent study summarized in the July 7th National Library of Medicine MedLine Plus suggested that testing for inherited abnormalities in DNA repair genes could provide patients and family members important information about their more »

High Prostate Cancer Risk Linked to Inherited Mutations in DNA-Repair Genes.

Mutations in DNA-repair genes, including the breast cancer genes BRCA1 and BRCA2, are involved in an inherited high risk of prostate cancer and, potentially, the risk of an aggressive cancer, according to researchers at Fred Hutchinson Cancer Research Center and the University of Washington. The study entitled, “Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer”,  published in The more »